迈得医疗：拟2000万至4000万元回购股份 用于减少注册资本

Group 1 - The company plans to repurchase shares using funds from its IPO surplus or its own funds, with the repurchased shares intended to reduce the registered capital [1] - The repurchase period is set for 12 months from the date the shareholders' meeting approves the repurchase plan [1] - The estimated number of shares to be repurchased ranges from approximately 833,300 to 1,666,700, representing about 0.50% to 1.00% of the company's total share capital [1] Group 2 - As of September 30, 2025, the company's total assets are 1.198 billion yuan, with net assets attributable to shareholders of 806 million yuan and current assets of 729 million yuan [1] - The estimated maximum repurchase funds will account for approximately 3.34%, 4.96%, and 5.49% of the respective financial data [1] - The company's debt-to-asset ratio stands at 29.86%, indicating that the repurchase will not significantly impact its debt repayment capability [1] Group 3 - The main business of the company is the research, production, sales, and service of medical consumables and intelligent equipment, integrating technology in medical device processes, automation, and software [1] - The company's primary products include safety infusion devices and blood purification equipment [1] - In the first three quarters of 2025, the company achieved total operating revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.8367 million yuan, a year-on-year increase of 15.82% [1]